Relay Therapeutics (RLAY) Total Current Liabilities (2019 - 2026)

Relay Therapeutics (RLAY) has 8 years of Total Current Liabilities data on file, last reported at $29.8 million in Q1 2026.

• Total Current Liabilities for Q1 2026 came in at $29.8 million, down 19.7% year-over-year; the trailing twelve-month figure through Mar 2026 was $29.8 million (down 19.7% YoY), and the FY2025 annual result was $25.6 million, down 49.58% from the prior year.
• Total Current Liabilities climbed to $29.8 million in Q1 2026 per RLAY's latest filing, from $25.6 million in the prior quarter.
• Over five years, Total Current Liabilities peaked at $71.6 million in Q2 2023 and troughed at $25.6 million in Q4 2025.
• A 5-year average of $46.0 million and a median of $43.9 million in 2022 frame the typical range for Total Current Liabilities.
• The sharpest annual moves came in 2022 and 2023: Total Current Liabilities jumped 161.95% in 2022, then tumbled 52.49% in 2023.
• A 5-year view of Total Current Liabilities shows it stood at $63.7 million in 2022, then plunged by 52.49% to $30.3 million in 2023, then jumped by 67.59% to $50.7 million in 2024, then sank by 49.58% to $25.6 million in 2025, then advanced by 16.31% to $29.8 million in 2026.
• Business Quant data shows RLAY's Total Current Liabilities at $29.8 million in Q1 2026, $25.6 million in Q4 2025, and $32.6 million in Q3 2025.